Who are Izervay™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo matching Pegcetacoplan, APL-2, Pegcetacoplan, ALXN1850, APL-2, ALXN2060.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/izervay.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Izervay™ — Competitive Intelligence Brief

Izervay™ (Izervay™) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C3 inhibitor. Area: Ophthalmology.

marketed Complement C3 inhibitor Complement C3 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Izervay™ (Izervay™) — Hoffmann-La Roche. Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Izervay™ TARGET	Izervay™	Hoffmann-La Roche	marketed	Complement C3 inhibitor	Complement C3
Placebo matching Pegcetacoplan	Placebo matching Pegcetacoplan	Swedish Orphan Biovitrum	phase 3	Complement C3 inhibitor (aptamer)	Complement C3
APL-2, Pegcetacoplan	APL-2, Pegcetacoplan	Apellis Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
ALXN1850	ALXN1850	Alexion Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
APL-2	APL-2	Apellis Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
ALXN2060	ALXN2060	Alexion Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement C3 inhibitor class)

Apellis Pharmaceuticals, Inc. · 3 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Izervay™ — Competitive Intelligence Brief. https://druglandscape.com/ci/izervay. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab